Knight Therapeutics (OTCMKTS:KHTRF) Trading Up 0.4% – Should You Buy?

Knight Therapeutics Inc. (OTCMKTS:KHTRF) traded up 0.4% during mid-day trading on Thursday . The stock traded as high as $6.6412 and last traded at $6.6020. Approximately 5,043 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 9,001 shares. The stock had previously closed at $6.5735.

Analyst Upgrades and Downgrades

Separately, Royal Bank Of Canada reissued an “outperform” rating on shares of Knight Therapeutics in a research note on Friday, May 8th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy”.

Knight Therapeutics Trading Up 0.4%

The firm’s fifty day simple moving average is $6.09 and its 200 day simple moving average is $5.10.

About Knight Therapeutics

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.